Fixed dose combinations for tuberculosis: Lessons learned from clinical, formulation and regulatory perspective

Area of Science:

• Pharmaceutical Sciences
• Infectious Diseases
• Public Health

Background:

• Tuberculosis (TB) control necessitates lengthy multi-drug therapy, often leading to poor patient compliance and the emergence of drug resistance.
• Fixed-dose combinations (FDCs) simplify TB treatment regimens, enhancing patient adherence and reducing the risk of resistance.
• Challenges in FDC quality, bioavailability, and regulatory approval hinder widespread implementation in national TB control programs.

Purpose of the Study:

• To review current knowledge on anti-TB FDCs, including their dosage, combinations, and clinical efficacy.
• To highlight the role of FDCs in improving patient compliance and preventing drug resistance in tuberculosis treatment.
• To discuss the quality and registration hurdles for FDCs and their implications for global TB control initiatives.

Main Methods:

• Literature review of existing clinical studies and experiences with fixed-dose combinations for tuberculosis therapy.
• Analysis of the impact of FDCs on patient compliance and the emergence of drug resistance.
• Examination of quality control, bioavailability, and registration requirements for FDCs in TB treatment.

Main Results:

• FDCs significantly improve patient compliance by reducing the pill burden in multi-drug therapy for TB.
• The Global Drug Facility (GDF) has adopted four FDCs as first-line treatments due to their advantages in TB control.
• Ensuring FDC quality and addressing registration requirements are critical for successful implementation and affordable access.

Conclusions:

• Fixed-dose combinations are essential tools for effective tuberculosis management, improving treatment outcomes and preventing resistance.
• Systematic attention to FDC quality and regulatory processes is necessary to facilitate their integration into national TB programs.
• Lessons learned from anti-TB FDCs can inform the development and selection of FDCs for other infectious diseases like malaria and AIDS.